Compare HBIO & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBIO | BOLD |
|---|---|---|
| Founded | 1901 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.7M | 25.7M |
| IPO Year | 2000 | 2024 |
| Metric | HBIO | BOLD |
|---|---|---|
| Price | $0.49 | $1.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $2.50 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 377.0K | 65.9K |
| Earning Date | 01-01-0001 | 06-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $116,176,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.80 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.28 | $0.96 |
| 52 Week High | $0.95 | $1.79 |
| Indicator | HBIO | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 33.59 | 46.52 |
| Support Level | $0.47 | $1.10 |
| Resistance Level | $0.55 | $1.20 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 6.33 | 25.00 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.